Ondansetron Aristo

Ondansetron, the active ingredient in Ondansetron Aristo, is a 5‑HT3 receptor antagonist presented as an oral formulation for oral use. It is employed to prevent nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative settings in adult patients.

GNH USA supplies Ondansetron Aristo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide. Our quality‑assured batches meet EU GMP standards and are shipped under controlled conditions to ensure product integrity. We provide regulatory documentation and support for import clearance in target markets.

Ondansetron is a 5‑HT3 receptor antagonist used to control nausea and vomiting in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of nausea and vomiting in patients receiving cytotoxic chemotherapy. - Radiotherapy‑induced nausea and vomiting: helps prevent nausea and vomiting associated with radiation treatment. - Postoperative nausea and vomiting: decreases the incidence of nausea and vomiting after surgical procedures.

Ondansetron may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT interval prolongation. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: agitation, hyperreflexia, tremor when combined with serotonergic agents.

When prescribing Ondansetron, clinicians should consider several precautionary measures to ensure safe use.

- Cardiac monitoring: assess baseline ECG in patients with known heart disease or electrolyte imbalance. - Drug interactions: avoid concomitant use with other QT‑prolonging agents. - Pregnancy: evaluate risk‑benefit ratio as safety data are limited. - Renal impairment: adjust dose in severe renal dysfunction. - Hepatic impairment: use with caution in moderate to severe liver disease. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Ondansetron can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other QT‑prolonging drugs: may increase risk of serious cardiac arrhythmia. - Apomorphine: can cause profound hypotension and loss of consciousness. - Serotonergic agents (e.g., SSRIs, MAO inhibitors): risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise ondansetron plasma levels. - CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic effect. - Anticholinergic agents: may diminish antiemetic efficacy.